Why Data, Trust, and Skills Are the Foundations of AI-Driven Pharmacoviginlance
Beena Wood, chief product officer at Qinecsa, argues that AI can revolutionize pharmacovigilance by detecting safety signals within hours across languages and geographies, but only if foundational data issues are solved. She highlights fragmented, non‑interoperable datasets as the primary barrier, noting that no amount of algorithmic sophistication can compensate for poor data quality. Trust and explainability are also critical, with regulators demanding transparency, auditability, and risk‑based evaluation under frameworks like the EU AI Act. Finally, Wood stresses that organizations must secure ROI, implement change‑management, and upskill staff to critically assess AI outputs.
Boltz PBC Launches with $28M to Democratize AI Platforms for Drug Discovery
Boltz, a public benefit corporation founded by MIT CSAIL researchers, announced a $28 million seed round led by Amplify, a16z and Zetta Venture Partners. The company aims to democratize AI‑driven drug discovery by offering Boltz Lab, an end‑to‑end platform that reduces...
Commercially Viable Biomanufacturing: Designer Yeast Turns Sugar Into Lucrative Chemical 3-HP
Scientists at the University of Illinois and Penn State have engineered the acid‑tolerant yeast *Issatchenkia orientalis* to convert plant sugars into 3‑hydroxypropionic acid (3‑HP) at commercial‑grade yields and titers. The strain achieved a 0.7 g 3‑HP per g glucose yield and 92 g 3‑HP...
NTLA’s 8‑K Reveals Liver Failure Death From Sepsis
Context: $NTLA just 8K'd (not a PR, hmmm wonder why) that their Hy's Law patient's autopsy showed ruptured GI ulcer and sepsis as the ultimate cause of death. Anyone saying this is not related to the liver failure is showing...
Aragen Launches CHOMax Cell Line Development and Manufacturing Platform
Aragen Biologics introduced CHOMax, an integrated cell line development and early manufacturing platform for standard IgG monoclonal antibodies. Refined across more than 200 CHO programs, the platform combines cell line creation, process development, analytics, and GMP manufacturing to move projects...
Flu Deaths Rise as Child Vaccination Rates Fall
1. There's a new FluView report from #CDC. Let's dive in. CDC was informed of 7 more kids who've died from #flu, bringing the season's toll to 17. Sadly, this number is going to rise. Vaccine uptake among kids has been...
Personalized Medicine Vs. Precision Medicine
Dr. Jennifer Levin Carter of Medzown clarified the distinction between personalized medicine, which tailors care to individual circumstances, and precision medicine, which leverages genetic and molecular data to design disease‑specific therapies. She highlighted oncology’s 15‑year transformation through genomics, enabling targeted...
A Bioinspired Hydrogel Patch with Controllable Adhesion Properties for Enhanced Soft Tissue Repair
Researchers from Shenzhen University, the Chinese Academy of Sciences and Hong Kong Polytechnic University have created a bioinspired hydrogel patch with controllable adhesion for soft tissue repair. The dual‑sided device combines a suction‑cup‑like adhesive layer that can be repositioned and...
Proteomics at Scale: Current Approaches and Emerging Technologies
The new eBook "Proteomics at Scale" examines how emerging and traditional proteomics platforms balance protein coverage with analytical detail. It highlights the inherent trade‑offs between detecting a broad protein repertoire and accurately quantifying proteoforms. The publication introduces Nautilus™’ Iterative Mapping...
BIO Investment Council Will Bring Together VC and Small Biotechs to Boost Innovation
The Biotechnology Innovation Organization (BIO) launched the BIO Investment Council (BIC) on Jan. 7 to bridge venture capital and small‑to‑mid‑size biotech firms. BIC aims to align early‑stage companies with the right investors as clinical‑stage funding now outpaces preclinical for the first...
Parkinson’s Outcomes Compared: With Vs. Without Deep Brain Stimulation
A recent comparative study evaluated Parkinson’s patients receiving deep brain stimulation (DBS) against those managed with medication alone. The analysis found that DBS recipients experienced a 40% reduction in OFF‑time and a 30% decrease in levodopa dosage, while motor scores...
Low Muscle Mass, Orthostatic Hypotension Linked in Parkinson’s
A recent multi‑center study of 200 Parkinson’s disease patients reveals that low skeletal muscle mass is strongly associated with orthostatic hypotension. Researchers found that 45% of participants with sarcopenia experienced significant blood‑pressure drops upon standing, compared with only 20% of...
Camizestrant
Camizestrant is an oral, selective estrogen‑receptor‑alpha (ERα) degrader developed by AstraZeneca for ER‑positive, HER2‑negative, ESR1‑mutated breast cancer. The drug advanced to a Phase 3 trial, with results published in the New England Journal of Medicine in June 2025. The study demonstrated a...
New Edible Film From Fish Waste Redefines Packaging
A research team has developed an edible film made from fish processing waste, turning discarded collagen and gelatin into a thin, biodegradable packaging material. The film dissolves in water within weeks, offering a direct alternative to single‑use plastics for food...
Orca Adds $250M in Financing to Back Launch of T Cell Therapy
Orca Bio announced it has raised $250 million in new financing to support the commercial launch of its T‑cell therapy designed to treat complications from allogeneic stem cell transplants. The capital infusion comes from a mix of venture capital firms and...
Biotech Deal Surge: Wnt, NLRP3, GLP‑1, and More
Your Weekly Biotech News Fix | Ep. 901 Designed to be consumed as a quick scroll 🧬 Parabilis - $305M Wnt bet 🔥 $LLY - Buys $VTYX (NLRP3) 🎯 $PFE - Cartography antigen deal 🧲 $AMGN - Dark Blue acquisition 🦠 $GSK / $IONS - HBV...
GRIm Score Predicts Nivolumab Efficacy in Melanoma
A recent multicenter trial found that the Glasgow Prognostic and Immune (GRIm) score reliably predicts response to nivolumab in advanced melanoma. Patients with high GRIm scores achieved a 45% objective response rate, while low‑score patients showed markedly shorter progression‑free survival....
Novartis to Build Fourth US Radiotherapy Factory in Florida
Novartis announced the construction of its fourth U.S. radiotherapy manufacturing facility, a 35,000‑square‑foot plant in Winter Garden, Florida. The new site is part of the company’s broader $23 billion pledge to expand domestic production across the United States. The factory will...
Tuina Vs. Physiotherapy: Pain Management in Chronic Back Pain
A new comparative review examines Tuina massage versus conventional physiotherapy for chronic back pain management. The analysis cites recent randomized trials indicating both modalities achieve similar reductions in pain intensity for mild-to-moderate cases. Tuina’s manual pressure and meridian focus contrast...
Smart Leggings Boost Muscle Strength in Seniors
A biotech startup unveiled smart leggings embedded with low‑level electrical stimulation and motion sensors that claim to increase muscle strength in adults over 65. In a 12‑week clinical trial, participants wearing the leggings improved grip strength by 15% and leg...
BioNTech, UPenn Team up for $50M Seed Fund
BioNTech and the University of Pennsylvania have announced a $50 million seed‑stage venture fund focused on mRNA‑based technologies. The fund will invest in early‑stage biotech startups, leveraging BioNTech’s commercial expertise and UPenn’s research capabilities. By targeting vaccine and therapeutic platforms, the...
Single-Cell Tests Predict Mycobacterial Infection Outcomes
A new study demonstrates that single‑cell transcriptional profiling can accurately predict outcomes of mycobacterial infections, distinguishing patients who will progress to active disease from those who remain latent. Researchers analyzed thousands of individual immune cells from blood samples, identifying distinct...
MTHFD2: Key to DNA Repair and LUAD Resistance
Researchers have identified the mitochondrial enzyme MTHFD2 as a pivotal driver of DNA repair mechanisms that enable lung adenocarcinoma (LUAD) cells to survive chemotherapy and targeted therapies. Experimental knockdown of MTHFD2 reduces homologous recombination efficiency and sensitizes tumors to platinum‑based...
System Can Diagnose Infections in 20 Minutes, Aiding Fight Against Drug Resistance
Researchers from the UK and China unveiled AutoEnricher, a microfluidic‑Raman platform that identifies bacterial and fungal pathogens in just 20 minutes. Validated on 305 patient samples, the system achieved 95 % accuracy and could detect mixed infections missed by conventional cultures....
A Bear’s Eye View of the Zanidatamab Data in Gastric Cancer
Jazz Pharmaceuticals presented zanidatamab data from the HERIZON‑GEA‑01 phase 3 trial at the ASCO GI Symposium, targeting HER2‑positive gastric cancer. The company touted the results as practice‑changing, prompting sell‑side analysts to echo the optimism. However, the stock fell 4‑5% as investors...
The Benefits of an Immune-Directed ADC Strategy
Lifordi Immunotherapeutics is pursuing an immune‑directed antibody‑drug conjugate (ADC) strategy that uses the VISTA protein to deliver potent steroids directly to immune cells. VISTA’s rapid internalization allows the ADC to release its payload intracellularly, aiming to avoid the systemic toxicities...
Krystal Biotech Says It Can Deliver Native Protein to Cystic Fibrosis Patients
Krystal Biotech announced early data showing its mutation‑agnostic platform can deliver functional native CFTR protein to the lungs of cystic fibrosis patients. In pre‑clinical models, the therapy restored up to 45% of normal chloride transport and reduced inflammatory markers. The...
Insmed Jumps on ‘Blowout’ Sales Beat for Bronchiectasis Drug Brinsupri
Insmed reported that its newly approved bronchiectasis therapy Brinsupri generated $144.6 million in Q4 2025 sales, nearly three times analyst forecasts. The surge was driven by roughly 9,000 new patients, bringing total users to about 11,500 and pushing the stock up 8%....
UCB Should Demand Label Change; Sonelokimab Inferior
“THAT WILL DECIMATE THE COMPETITION” If the FDA is dumb enough to put a 29% delta on the $MLTX label, UCB should simply request a label change to include *their* P2 efficacy data on the label….where their delta was ***36%***. 36>29 for...
J&J Strikes Drug Pricing, Tariff Deal with the White House
Johnson & Johnson has become the latest pharmaceutical company to sign a "most‑favored‑nation" pricing agreement with the White House. The deal commits J&J to lower the list prices of a portfolio of high‑cost drugs for federal programs, including Medicare and...
Roche Spends $570M on Another ADC Agreement With China’s MediLink
Roche has agreed to pay $570 million in upfront and near‑term milestone fees to secure exclusive worldwide rights—except mainland China, Hong Kong and Macau—to MediLink’s B7H3‑targeted antibody‑drug conjugate YL201. The ADC, which carries a camptothecin‑derived cytotoxin, is advancing in registrational studies for...
J&J Jumps on the MFN Pricing Train
Johnson & Johnson has become the latest pharmaceutical company to sign a Most‑Favoured Nation (MFN) drug‑pricing agreement with the Trump administration, securing an exemption from looming tariffs. The deal, the 15th of its kind, will make J&J medicines available through...
Rampart Closes Down Less Than 2 Years After Launch
Rampart Bioscience, a stealth startup that raised $85 million in a Series A round to develop a non‑viral DNA‑based therapy platform called HALO, has shut down less than two years after emerging from stealth. The company’s website and LinkedIn page have been...
The 4x Rule: Why some People’s DNA Is More Unstable than Others
Researchers analyzed nearly one million genomes and found that short DNA repeats steadily lengthen with age. Inherited genetic variants can accelerate or decelerate this expansion by up to four‑fold, creating substantial individual differences. The study uncovered a previously unknown repeat...
ASND Combo Shows Robust Growth, Heads to Phase 3
$ASND -2.5% Looks approvable (priority review; class precedent). Combo = upside optionality, not the label. COACH Wk-52 open-label Ph2 (n=21) CNP + hGH >AGV: 8.8 (naïve) / 8.42 cm/yr (prior-CNP), >97th pct vs avg-stature >Z-score: +1.02 / +0.86; proportionality/arm-span up; bone age “consistent” >AEs...
Predicting $20B+ Biotech M&A Deal by 2026
One of my #JPM26 predictions for 2026 is that we'll see a $20B-plus M&A deal in biotech. So here's hoping any RevMed deal comes after Monday morning. https://t.co/5pe4ymAILt
InflaRx Stanches Spending With 30% Staff Reduction, Priority Pivot
InflaRx announced a restructuring that will eliminate roughly 30% of its workforce and incur about $7 million in one‑time, largely non‑cash, costs. The company is pulling funding from its COVID‑19 antibody Gohibic and redirecting resources toward izicopan, an oral C5a‑receptor inhibitor...
Sepsis Often Leads to Death In
Hey @grok is sepsis a common proximate cause of death in patients with drug induced liver failure?
CHIP Clones Raise Cardiovascular Risk in Cancer Survivors
More evidence that blood stem cell clones (CHIP), common with increasing age, increase the risk of cardiovascular events, from people treated with cancer https://t.co/56YDjxshjg https://t.co/kdUksoCFmI
Roche Returns to Chinese Biotech MediLink for Another ADC Pact
Roche has entered a second licensing agreement with Chinese biotech MediLink, this time to develop an antibody‑drug conjugate (ADC) that targets the B7‑H3 antigen on solid tumours. The deal builds on a prior partnership focused on earlier‑stage oncology assets and...
Red Blood Cells Drive Vascular Damage in Long‑Term Type 2 Diabetes
Implicating red cells as an underpinning of the vascular damage seen with long duration Type 2 diabetes https://t.co/FzvmreCtn7 https://t.co/MdgpHmpRvo
Nominate Under‑35 Biotech Trailblazers for 2026 Award
Do you know an up and coming someone killing it in biotech? If they're under 35 years of age, please nominate them for the 2026 Technology Review 35 Innovators Under 35 Award. (or just email me. address is in bio) https://t.co/90fwj4GjNU
AirNexis Gets $200M to Test China-Derived COPD Drug
AirNexis, a Palo Alto biotech, announced a $200 million financing round to launch clinical testing of a chronic obstructive pulmonary disease (COPD) therapy derived from Chinese research. The capital, sourced from a mix of U.S. and Chinese investors, will fund Phase 2/3...
Zanidatamab Gastric Cancer Data Faces Seven Bearish Concerns
It's good to see new trial readouts at #GI26, although there are 7 reasons to be bearish about the zanidatamab data in gastric cancer: https://t.co/g2MbrPI7Iu https://t.co/tBY2yJ6YMe
APOE Ε3/Ε4 Alleles Drive Majority of Alzheimer’s Cases
A new report claims that the APOE gene alleles accounts for the vast majority of Alzheimer's cases: "Without strong underlying risks from APOE ε3 and ε4, almost all AD and half of all dementia would not occur." https://t.co/KgRFx36WOn
Linking DNA Mutations to Gene Expression in Single Cells
Genotype-to-phenotype mapping of somatic clonal mosaicism via single-cell co-capture of DNA mutations and mRNA transcripts https://t.co/6Lss1ukbvp https://t.co/bGwnmQEYfI
US Cuts Childhood Vaccines, Lagging Behind Peers
Did slashing multiple vaccines from the childhood vaccine schedule bring the US in line with other countries? In a word, no. The US now recommends all kids be protected against fewer diseases than South Korea, Israel, Saudi Arabia, Taiwan &...
AI Accelerates Answers, but Domain Knowledge Solves Problems
1/ AI tools are useless if you don't know what you're looking for. I use Perplexity for search. But the AI didn't solve my IGV bug - my domain knowledge did. The AI just helped me find the answer faster. https://t.co/zi2e2FbO5O
UniQure Secures FDA Type A Meeting
$QURE +13% uniQure Announces Type A Meeting Scheduled with FDA 🍿 uniQure Announces Type A Meeting Scheduled with FDA https://t.co/iqZkaNYD7Z https://t.co/lRcR6vgV0D
U.S. Becomes Outlier in Global Vaccine Schedules
Fact check: When it comes to vaccine schedules, the U.S. is now the outlier STAT analysis shows top officials have put the country out of step with peer nations By @HelenBranswell https://t.co/t8ZmqatU1U